“If you’ve paid half a million dollars for drugs and half a million dollars for care, and a year later your cancer is back, is that a good deal?” asked Leonard Saltz, chief of gastrointestinal oncology at Memorial Sloan Kettering Cancer Center in New York.
The goal of the business is to help physicians identify the most suitable combinations of FDA-approved treatments that can be immediately prescribed.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
At $475,000, the therapy isn't cheap but for its part, Novartis has said patients would only pay the full whack if they respond to the therapy by the end of the first month.
“From what we’re hearing, this will be a quantum leap more expensive than other cancer drugs,” said Leonard Saltz, chief of gastrointestinal oncology at Memorial Sloan Kettering Cancer Center in New York.
“We showed that cancer stem cells co-opt an RNA editing system to clone themselves. What’s more, we found a method to dial it down,” said principal investigator Dr. Catriona Jamieson, of UC San Diego School of Medicine.
Also, the College of Healthcare Information Executives has created the CHIME Cybersecurity Center and Program Office, and ProofPilot CEO talks about the challenge of balancing digital health startup investor expectations with those of customers.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
With information from one of the most intense cancer research studies ever conducted (surveying 25.7 million people), it’s clear that where you live has something to do with how likely you are to survive cancer. For example, 9 out of 10 kids with lymphblastic leukemia in the U.S. will survive. Compare that to the 16 […]
Cancer cells are sneaky and, unfortunately, smart enough to develop a host of ways to escape the body’s defense mechanisms. A startup called Oncotide Pharmaceuticals is hoping to outsmart some cancer cells by modulating a certain kind of protein phosphatase that impedes the ability of cancer cells to grow and replicate. That phosphatase is PP2A, […]
Leukemia treatment Arzerra, developed by GlaxoSmithKline (NYSE:GSK) and drug partner Genmab (CSE:GEN), has been submitted for approval in Japan. Arzerra has currently received regulatory approval in the United States and Europe to treat chronic lymphocytic leukemia (CLL), a type of leukemia that progresses more slowly as it targets lymphocytes in the body’s immune system. CLL […]
The U.S. Food and Drug Administration has approved a new test for blood donations, just the second test available to screen for two viruses linked to leukemia and neurologic disorders. The blood test, developed by medical device company Avioq, detects antibodies to human T-lymphotropic virus type 1 (HTLV 1) and human T-lymphotropic virus type 2 […]
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Formula Pharmaceuticals is raising $13 million in a series B financing round for a vaccine to be used during first remission for acute myeloid leukemia and other aggressive cancers. The investment will be used to support the two Phase II clinical trials of the multi-peptide immunotherapeutic at Memorial Sloane-Kettering Cancer Center that will take two years. Although […]
Eusa Pharma, a British drug development company with its North American headquarters in Langhorne, Pennsylvania, has received approval from the U.S. Food and Drug Administration for its orphan drug Erwinaze for patients with acute lymphoblastic leukemia who suffer from allergic reactions to chemotherapy drugs derived from E.Coli. Acute lymphoblastic leukemia is a cancer in which […]